Profile data is unavailable for this security.
About the company
Formosa Laboratories, Inc. is a Taiwan-based company principally engaged in the development, production and distribution of ultraviolet (UV)-proof active ingredients, bulk pharmaceutical chemicals, antibody drug conjugates, as well as the provision of customized services. The Company primarily provides UV-proof active ingredients series products, vitamin D derivative series products, anti-inflammatory analgesic series products, steroid, anti-cancer drugs, cholesterol phosphate binding agents, nuclear magnetic resonance (NMR) reagents, respiratory disease drugs, central nervous system drugs, immune system regulators and weight loss drugs, as well as customized research and development and original equipment manufacturing (OEM) services. The Company distributes its products to Europe, the Americas, Asia and other markets.
- Revenue in TWD (TTM)4.59bn
- Net income in TWD392.86m
- Incorporated1995
- Employees480.00
- LocationFormosa Laboratories IncNo.36, Hoping Street, Kengkou VillageTAOYUAN 338TaiwanTWN
- Phone+886 33240895
- Fax+886 33240945
- Websitehttps://www.formosalab.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cenra Inc | 8.94bn | 371.76m | 5.66bn | 1.40k | 25.41 | 0.756 | 7.83 | 0.6338 | 1.50 | 1.50 | 34.28 | 50.26 | 0.7106 | 2.15 | 5.73 | -- | 2.97 | 3.69 | 4.29 | 4.96 | 37.10 | 36.56 | 4.18 | 5.50 | 0.7054 | -- | 0.2976 | 52.77 | 1.40 | 2.50 | -32.51 | -2.72 | 3.57 | -8.97 |
| Formosa Pharmaceuticals Inc | 137.46m | -200.59m | 5.87bn | -- | -- | 3.66 | -- | 42.72 | -1.49 | -1.49 | 1.02 | 10.62 | -- | -- | -- | -- | -- | -40.34 | -- | -44.21 | 84.63 | -- | -145.95 | -2,488.28 | -- | -- | 0.0167 | -- | 2,270.49 | -- | 20.75 | -- | -42.98 | -- |
| Panion & BF Biotech Inc | 2.04bn | 121.33m | 7.66bn | 321.00 | 63.14 | 4.07 | 26.30 | 3.76 | 1.41 | 1.41 | 23.73 | 21.94 | 0.6546 | 1.72 | 9.66 | -- | 3.90 | 4.08 | 5.72 | 5.63 | 52.43 | 52.37 | 5.96 | 5.93 | 0.8804 | 16.87 | 0.2717 | 111.06 | -21.54 | 5.96 | -57.65 | -13.47 | 35.39 | -3.23 |
| Formosa Laboratories Inc | 4.59bn | 392.86m | 9.46bn | 480.00 | 24.22 | 1.22 | 12.43 | 2.06 | 3.25 | 3.25 | 38.06 | 64.43 | 0.3372 | 1.45 | 4.82 | -- | 1.88 | 2.68 | 2.58 | 3.61 | 43.88 | 35.40 | 5.56 | 8.75 | 1.41 | 0.5789 | 0.3074 | 27.38 | 15.80 | 10.16 | -69.16 | -6.52 | -11.60 | 32.22 |
| Adimmune Corp | 1.66bn | -607.92m | 9.60bn | 564.00 | -- | 1.87 | -- | 5.80 | -1.44 | -1.44 | 3.93 | 11.92 | 0.1848 | 1.25 | 4.04 | -- | -8.27 | 0.6867 | -10.19 | 0.7739 | 27.82 | 30.11 | -44.75 | 3.04 | 1.99 | -24.75 | 0.3284 | 32.80 | -20.72 | 16.77 | -319.91 | -- | 38.05 | -- |
| Standard Chem & Pharm Co Ltd | 6.71bn | 847.58m | 11.42bn | 1.13k | 13.48 | 1.93 | 7.13 | 1.70 | 4.74 | 4.74 | 37.50 | 33.05 | 0.6066 | 2.39 | 6.00 | -- | 10.98 | 9.68 | 20.02 | 17.61 | 43.81 | 43.75 | 18.10 | 17.02 | 1.93 | -- | 0.0795 | 60.34 | 6.64 | 11.80 | 2.39 | 17.40 | 29.97 | 12.47 |
| SCI Pharmtech Inc | 1.41bn | 484.24m | 11.71bn | 241.00 | 24.55 | 2.16 | 16.70 | 8.29 | 3.99 | 3.99 | 13.98 | 45.36 | 0.2211 | 1.82 | 4.61 | -- | 7.58 | 6.90 | 8.56 | 8.26 | 27.11 | 38.18 | 34.26 | 19.85 | 1.68 | 9.22 | 0.1692 | 42.38 | 33.83 | -9.10 | -4.55 | -8.00 | 44.67 | -16.35 |
| Holder | Shares | % Held |
|---|---|---|
| Cathay Securities Investment Trust Co., Ltd.as of 30 Sep 2024 | 6.68m | 5.56% |
| Dimensional Fund Advisors LPas of 07 Nov 2024 | 2.97m | 2.47% |
| Nippon Life India Asset Management Ltd. (Invt Mgmt)as of 31 Oct 2024 | 462.17k | 0.38% |
| American Century Investment Management, Inc.as of 07 Nov 2024 | 169.00k | 0.14% |
| Dimensional Fund Advisors Ltd.as of 31 Aug 2024 | 127.58k | 0.11% |
| Mellon Investments Corp.as of 07 Nov 2024 | 117.00k | 0.10% |
| SSgA Funds Management, Inc.as of 07 Nov 2024 | 68.72k | 0.06% |
| DFA Australia Ltd.as of 30 Sep 2024 | 27.98k | 0.02% |
| Mackenzie Investments Corp. (United States)as of 31 Aug 2024 | 6.00k | 0.01% |
| Irish Life Investment Managers Ltd.as of 07 Nov 2024 | 1.77k | 0.00% |
